Clinical Development
Vision
Strategy
SHIONOGI continues to create medicines with excellent efficacy and safety as a research-driven pharmaceutical company,SHIONOGI has delivered medicines developed in Japan to patients around the world.
In infectious diseases, we leverage our knowledge and experience we have gained through the development of medicines for antimicrobial resistance (AMR: Antimicrobial Resistance) and COVID-19, and our mission is to continue meeting the expectations of society.
We are also accelerating the creation of innovative healthcare solutions through the expanding into QOL (Quality of Life) diseases, the utilization of digital technologies, and collaboration with external partners.
Furthermore, we are committed to the development of rare diseases driven by unmet medical needs, strengthening our structure to contribute to patients globally.
We will continue to development "the best possible products needed to protect people’s health" and contribute to society as an entity that creates the future of healthcare.